One-month regimen of daily rifapentine (600 mg) plus isoniazid (300 mg) (1HP) is an attractive preventive strategy for PLWH with latent TB infection (LTBI). However, the optimal integrase strand transfer inhibitor-based regimens in combination with 1HP remain unknown. We aimed to assess the completion rate, bictegravir (BIC) trough concentration, cytokine profile, and virologic response in PLWH with LTBI who received 1HP and BIC/FTC/TAF concurrently.
PLWH were enrolled who tested positive by interferon gamma release assay (IGRA) and had received BIC/FTC/TAF for at least 2 weeks with plasma HIV RNA load (PVL) <200 copies/mL within 6 months of initiation of 1HP. BIC trough concentrations were determined with the use of LC-MS/MS before the first dose (Day 1), 24 hours after the 14th (Day 15) and 28th (Day 29) doses of 1HP; and PVLs were determined within 6 months before and 2 weeks after 1HP initiation (Day 15), end of 1HP (Day 29), and 3 months after 1 HP discontinuation. Cytokine levels were determined with the use of commercial kits on Day 1, Day 15, and Day 29.
From November 2019 to November 2020, a total of 1832 PLWH tested for LTBI with 59 (3.2%) being positive by IGRA. Fifty PLWH with LTBI who had received BIC/FTC/TAF for at least 2 weeks were enrolled for 1HP treatment (98% men and 90% MSM). Only one patient (2.0%) discontinued 1HP on Day 15 due to fever and generalized rashes; more than 5-fold increases of the IFN-gamma, IL-6, TNF-alpha, and IL-10 levels were observed. Statistically insignificant increases of the cytokines assessed were observed in the remaining PLWH. Sequential changes of BIC trough concentrations after 1HP initiation were determined in 48 PLWH (Figure). The percentages of BIC trough concentration above the protein-adjusted 95% effective concentration (paEC95=162 ng/mL) were 56.3% on Day 15 and 35.4% on Day 29. PVLs were <200 and <50 copies/mL in 100% and 97.9% of the enrolled PLWH before 1HP initiation (median 20 copies/mL and range 20-85 copies/mL), 91.7% and 72.9% on Day 15 (median 20 copies/mL and range 20-423 copies/mL), 97.9% and 91.5% on Day 29 (median 20 copies/mL, range 20-205 copies/mL), and 100% and 97.7% 3 months after 1HP discontinuation (median PVL 20 copies/mL, range 20-57 copies/mL), respectively.
BIC concentrations were significantly decreased with concurrent use of 1HP among PLWH with LTBI.
![]()